Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.

ABSTRACT: The increased incidence and prevalence of neuroendocrine tumors (NETs) over the past few decades has been accompanied by an improvement in overall survival. There are differences in the management of small bowel NETs versus pNETs. The management of all patients with NETs must be individualized based on patient characteristics as well tumor-related factors. This article reviews the role of somatostatin analogues, historical results with chemotherapy in gastroenteropancreatic NETs (GEPNETs), and more recent evidence for the use of cytotoxic chemotherapy in GEPNETs. The article also discusses molecular targeted therapies approved for use in GEPNETs and some ongoing clinical trials.

SUBMITTER: Chandrasekharan C 

PROVIDER: S-EPMC7700751 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature